Infectious Disease

Instances of anaphylaxis are uncommon with the primary 1.9 million COVID-19 vaccinations

January 06, 2021

2 min read

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

As of December 23, there were 21 confirmed cases of anaphylaxis among the first 1,893,360 recipients of the Pfizer / BioNTech COVID-19 vaccine in the US, the CDC and FDA reported in MMWR.

This equates to a rate of 11.1 cases of anaphylaxis per 1 million doses of COVID-19 vaccine, compared to 1.3 cases per 1 million influenza vaccinations Nancy E. Messonnier, MD, Director of the National Center for Immunization and Respiratory Diseases of the CDC.

Covid vaccination

The anaphylaxis rate among those vaccinated with the Pfizer-BioNTech COVID-19 vaccine is 13.1 per 1 million doses.
Photo credit: Adobe Stock

“That may seem high, but it is still a rare result,” Messonnier said during a press conference on Wednesday.

“We know that safety is one of the top public concerns about COVID-19 vaccines,” Messonnier said. ‚ÄúSafety has been of paramount importance throughout the development process, and the continued safety of these vaccines when given to the public is of paramount importance to the federal government. Ensuring public knowledge and confidence in the safety of these vaccines, both initially and during prolonged use, is an essential part of our national vaccination efforts. “

Nancy E. Messonnier

According to the report, more than 4,000 adverse events were observed after vaccination with Pfizer and BioNTech’s Messenger RNA-based COVID-19 vaccine. Of these, 21 cases of anaphylaxis were confirmed. The report stated that those who developed anaphylaxis were on average 40 years old, had symptoms about 13 minutes after vaccination, and had a history of food, medication, or insect allergies. No clustering was observed, according to Messonnier, and patients with anaphylaxis varied based on location and vaccine lots. Of the 20 patients with available follow-up data, all had recovered or had been discharged home.

Following the appearance of these data, the CDC released updated Preliminary Clinical Considerations for the use of vaccines currently approved in the United States and preliminary considerations for preparing for the potential management of anaphylaxis. According to the study, in addition to screening for contraindications and precautions prior to administering COVID-19 vaccines, vaccination centers should have the necessary resources to treat anaphylaxis, have post-vaccination observation periods, and give people with anaphylaxis signs and symptoms immediately with intramuscular injection treat adrenaline.

Messonnier said some adverse events are random and may not be related to the actual vaccine.

“I know I’m looking forward to the day when I can roll up my sleeve and get vaccinated,” she said.

References:

press conference

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

COVID-19 Resource Center

COVID-19 Resource Center

Related Articles